Anti-VEGF Receptor 2 antibody (ab39256)
- Datasheet
- References (33)
- Protocols
Overview
-
Product nameAnti-VEGF Receptor 2 antibody
See all VEGF Receptor 2 primary antibodies -
DescriptionRabbit polyclonal to VEGF Receptor 2
-
Host speciesRabbit
-
Tested applicationsSuitable for: IHC-FoFr, IHC-P, WBmore details
-
Species reactivityReacts with: Mouse, Rat, Human
-
Immunogen
Synthetic peptide conjugated to KLH derived from within residues 1200 - 1300 of Human VEGF Receptor 2.
Read Abcam's proprietary immunogen policy (Peptide available as ab39255.) -
Positive control
- This product gave a positive signal in HUVEC whole cell lysate.
Properties
-
FormLiquid
-
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4 -
Concentration information loading... -
PurityImmunogen affinity purified
-
ClonalityPolyclonal
-
IsotypeIgG
-
Research areas
Associated products
-
Compatible Secondaries
-
Immunizing Peptide (Blocking)
-
Isotype control
Applications
Our Abpromise guarantee covers the use of ab39256 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| IHC-FoFr | Use at an assay dependent concentration. | |
| IHC-P | 1/250. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. | |
| WB | Use a concentration of 1 µg/ml. Detects a band of approximately 220 kDa (predicted molecular weight: 152 kDa).Can be blocked with Human VEGF Receptor 2 peptide (ab39255). |
Target
-
FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
-
Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
-
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localizationMembrane.
- Information by UniProt
-
Database links
- Entrez Gene: 3791 Human
- Entrez Gene: 16542 Mouse
- Entrez Gene: 25589 Rat
- Omim: 191306 Human
- SwissProt: P35968 Human
- SwissProt: P35918 Mouse
- SwissProt: O08775 Rat
- Unigene: 479756 Human
see all -
Alternative names
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
Images
-
Western blot - Anti-VEGF Receptor 2 antibody (ab39256)Anti-VEGF Receptor 2 antibody (ab39256) at 1 µg/ml + HUVEC (Human Umbilical Vein Endothelial Cell) Whole Cell Lysate at 20 µg
Secondary
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Predicted band size: 152 kDa
Observed band size: 220,230 kDa why is the actual band size different from the predicted?
Additional bands at: 31 kDa. We are unsure as to the identity of these extra bands. -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-VEGF Receptor 2 antibody (ab39256)This image is courtesy of an Abreview submitted by Antibody Solutions Ltd.ab39256 staining VEGF Receptor 2 in Human breast carcinoma tissue sections by IHC-P (Formaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 5 minutes of peroxidase block followed by 10 minutes of protein block at 20°C; antigen retrieval was heat mediated in retrieval solution. Samples were incubated with primary antibody (1/250 in antibody diluent) for 45 minutes at 20°C. An undiluted HRP-conjugated polymer goat anti-mouse/rabbit IgG polyclonal polymer was used as secondary antibody. -
Immunohistochemistry (PFA perfusion fixed frozen sections) - Anti-VEGF Receptor 2 antibody (ab39256)This image is a courtesy of Sophie Pezetab39256 staining VEGF Receptor 2 in rat heart tissue section by Immunohistochemistry (PFA perfusion fixed frozen sections). Tissue underwent fixation with 4% PFA and it was later postfixed overnight in the same fixative. It was then cryoprotected in 30% sucrose and cut using a cryostat. The primary antibody was diluted 1/100 and incubated with sample for 18 hours at 20°C in PBS + 0.3 % Triton X100. An Alexa Fluor® 488 - conjugated goat polyclonal to rabbit IgG was used at dilution at 1/1000 as secondary antibody.
References
This product has been referenced in:
- Pattanaik S et al. Vascular Tissue Engineering Using Scaffold-Free Prevascular Endothelial-Fibroblast Constructs. Biores Open Access 8:1-15 (2019). Read more (PubMed: 30637179) »
- Smeda M et al. Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice. Breast Cancer Res 20:86 (2018). Read more (PubMed: 30075800) »
